Video

Dr. Niu on Combining Immunotherapy With VEGF Inhibitors in ES-SCLC

Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.

Jason Niu, MD, PhD, director, Lung Cancer Program, Banner MD Anderson Cancer Center, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer (ES-SCLC).

Combining immunotherapy with VEGF inhibitors has shown efficacy in other tumor types, says Niu.

For example, the combinations of pembrolizumab (Keytruda)/axitinib (Inlyta) and avelumab (Bavencio)/axitinib have been approved for the first-line treatment of patients with advanced renal cell carcinoma. Additionally, bevacizumab (Avastin) plus atezolizumab (Tecentriq) elicited a survival benefit for patients with advanced hepatocellular carcinoma.

It is likely that all patients with ES-SCLC will receive immunotherapy up front based on the positive findings from the phase 3 IMpower133 and CASPIAN studies, says Niu.

However, additional research is needed to determine which immunotherapeutic agent should be given to patients who progress in the first-line setting. There could be clinical rationale to implement immunotherapy/VEGF inhibitor combinations in this setting, concludes Niu.

Related Videos
Dr Patel on the Utility of the IPS Test in Solid Tumors
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD